CTRI/2017/04/008420已完成2 期
â??Open labeled, controlled, randomized evaluation of adjuvant effect of triturated Dhatri Nisha Yoga in management of Prameha vis a vis Diabetes Mellitus (Type II).â??
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Cases of both genders will be included.
- •A known diabetic (Diabetes Mellitus type II) on OHA or Insulin therapy treatment.
- •Patients presenting classical symptoms of Prameha.
- •Patient with fasting blood sugar more than 150 mg% and post prandial blood sugar more than 200 mg%.
- •Patient showing mild to poor control in HbA1c test
- •Patients having chronic complications like Nephropathy, Neuropathy and Retinopathy
排除标准
- •Patients with fasting blood sugar less than 150 mg% and post prandial blood sugar less than 200mg%.
- •Pregnant and lactating mothers.
- •Patients having acute complications like Hyperglycemic coma, Ketoacidosis, and infections like gangrene.
- •Insulin Dependent Diabetes Mellitus (IDDM) and those patients who are under insulin therapy
- •Patients suffering from other diseases such as Tuberculosis, Cardiac diseases, HIV.
研究者
相似试验
已完成
2 期
Effect of Dhatri nisha yoga in Prameha (Diabetes Mellitus Type II).CTRI/2017/05/008461Pune District Education Associations College of ayurved and research centre nigdi pune68
招募中
2 期
Clinical Study of the effect of Vidangadi Ghanavati in Prameha (Diabetes Mellitus Type II).CTRI/2015/04/005719PDEAs College of ayurved and research centre nigdi pune60
招募中
2 期
Evaluation of added effect of Dhatrinisha Vati in Madhumeha i.e.Diabetes Mellitus type- IICTRI/2016/08/007185Maharashtra Arogya Mandals Sumatibhai Shah Ayurved Mahavidyalaya60
已完成
不适用
Open-label, randomized, controlled study evaluating dose-escalation of peginterferon alpa-2b plus ribavirin in aged patients with chronic hepatitis CChronic hepatitis CJPRN-UMIN000015230Okayama University Hospital100
已完成
不适用
CLBS12-P01Patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) and patients with CLI due to Buerger's Disease (BD)JPRN-jRCT1080223694EPS Corporation (Global Sponsor: Caladrius Biosciences, Inc.)35